Healthcare Stocks

SUDA Pharmaceuticals (ASX:SUD) Reaches Key Milestones in September 2020 Quarter

 SUDA Pharmaceuticals (ASX:SUD) Reaches Key Milestones in September 2020 Quarter

Summary SUDA Pharmaceuticals Ltd (ASX:SUD) recently released its quarterly activities report for the first-quarter FY 2021. The quarter marked the attainment of two important milestones for the anagrelide program and receipt of TGA approval for...

Read More...
Scan Through SUDA’s Key Operational Achievements in FY 2019-2020

Scan Through SUDA’s Key Operational Achievements in FY 2019-2020

Summary SUDA reported key operational achievements for FY 2019-2020. The Company finalised a key agreement with Cann Pharma Australia during the year. The financial year also saw the signing of three significant agreements with Sanofi, Ordesa ...

Read More...
SUDA Closed Entitlement Offer Substantially Oversubscribed, Reported June 2020 Qtr Achievements

SUDA Closed Entitlement Offer Substantially Oversubscribed, Reported June 2020 Qtr Achievements

Summary SUDA’s Entitlement Offer to raise ~$3.56 million has been strongly supported by its shareholders and closed substantially oversubscribed. The Company will now issue ~142.25 million shares and 47.4 million listed options in line wi...

Read More...
SUDA Reaches Major Milestone with Grant of TGA Approval for ZolpiMist<sup>TM</sup>, Stock Rallies Above 150%

SUDA Reaches Major Milestone with Grant of TGA Approval for ZolpiMistTM, Stock Rallies Above 150%

SUDA Pharmaceuticals Limited (ASX:SUD) soared above 150 per cent to $0.068 on ASX on 29 July 2020, following the announcement regarding grant of Therapeutics Goods Administration’s (TGA) approval for ZolpiMistTM (zolpidem tartrate). Notably, ...

Read More...
SUDA Seeking Participation in $3.56M Capital Raising, Eyeing development of Anagrelide and OroMist Assets

SUDA Seeking Participation in $3.56M Capital Raising, Eyeing development of Anagrelide and OroMist Assets

SUDA Pharmaceuticals Limited (ASX:SUD), the global leader in reformulating and delivering medication via the oral mucosa is seeking shareholders’ support to participate in the capital raising activity announced in early July 2020. On 3rd Jul...

Read More...
SUDA Announces $3.56 Million Capital Raising to Fund Development of its Key Assets

SUDA Announces $3.56 Million Capital Raising to Fund Development of its Key Assets

Australia’s oro-mucosal drug delivery leader, SUDA Pharmaceuticals Limited (ASX:SUD) has recently announced a non-renounceable entitlement offer to raise about $3.56 million via issue of ~142 million new ordinary shares in SUDA, at an attract...

Read More...
SUDA Reports Significant Preliminary Results from Anagrelide Pharmacokinetic Study

SUDA Reports Significant Preliminary Results from Anagrelide Pharmacokinetic Study

Summary SUDA made further progress towards Anagrelide program, attaining significant preliminary results from a pharmacokinetic study. Results support SUDA’s hypothesis that Anagrelide’s mouth spray formulation can lessen the risk o...

Read More...
Japanese Patent Office Accepted SUDA’s Anagrelide Cancer Patent Application; Stock Surged Over 10%

Japanese Patent Office Accepted SUDA’s Anagrelide Cancer Patent Application; Stock Surged Over 10%

The Japanese Patent Office has accepted Anagrelide cancer patent application, and the patent would now proceed to grant, notified SUDA Pharmaceuticals Ltd (ASX:SUD) in its latest update. The patent “Use of Anagrelide for Treating Cancer” ...

Read More...
SUDA Expects TGA Review Completion for ZolpiMist™ by Q4 2020

SUDA Expects TGA Review Completion for ZolpiMist™ by Q4 2020

SUDA Pharmaceuticals Limited (ASX:SUD), an Australia-based oro-mucosal drug delivery player, notified in its latest update that the Therapeutic Goods Administration (TGA) review for its insomnia drug ZolpiMistTM is expected to be completed by Q4 2020...

Read More...
SUDA’s March Quarter Report Card Out! Let’s Browse Through Key Developments

SUDA’s March Quarter Report Card Out! Let’s Browse Through Key Developments

Oro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) has announced another set of robust quarterly results for the third quarter of FY2020. During the period, the Company made considerable progress in line with the 2020 targets h...

Read More...
SUDA Pharmaceuticals Discovering Use of Anagrelide as Adjuvant Therapy in Treating Cancer

SUDA Pharmaceuticals Discovering Use of Anagrelide as Adjuvant Therapy in Treating Cancer

Pills, capsules, and tablets may not be the most efficient method for administering medicines as only ~10 – 30 per cent of the drug reaches the bloodstream. Several factors, including food effect, enzymatic degradation and first-pass metabolism...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK